Drug interactions and pharmacokinetics: latest news

Drug interactions and pharmacokinetics resources

Drug interactions and pharmacokinetics features

Drug interactions and pharmacokinetics news from aidsmap

  • Lower daily tenofovir dose of 150mg safe and effective in people with moderate renal impairment

    A reduced tenofovir (Viread) dose of 150mg daily appears to be a safe and effective treatment for people with HIV who have moderate renal impairment, investigators from Thailand report in the online edition of Clinical Infectious Diseases. The 150mg daily ...

    22 May 2015 | Michael Carter
  • Sofosbuvir/ledipasvir raises some antiretroviral levels in HIV/HCV coinfected people

    People with HIV and hepatitis C virus (HCV) co-infection who take sofosbuvir/ledipasvir (Harvoni) to treat hepatitis C along with boosted protease inhibitor antiretroviral regimens may experience changes in drugs levels, but these are mostly not considered clinically relevant, according ...

    10 March 2015 | Liz Highleyman
  • Efavirenz compromises hormonal contraceptive implant

    The widely prescribed non-nucleoside reverse transcriptase inhibitor (NNRTI) efavirenz substantially reduces levels of the hormonal contraceptive levonorgestrel, a component of a progesterone contraceptive implant widely used in developing countries, according to findings from a study conducted in Uganda presented ...

    03 November 2014 | Keith Alcorn
  • High incidence of antiretroviral prescribing errors in Nigeria

    Antiretroviral prescribing errors are common in Nigeria, according to results of a large prospective study published in PLOS ONE. Errors were detected in the prescriptions of almost all adult patients. Common errors included prescribing incorrect antiretroviral drugs or combinations; prescribing drugs ...

    07 February 2014 | Michael Carter
  • Ritonavir the cause of the interaction between telaprevir and ritonavir-boosted atazanavir

    Ritonavir is the cause of the detrimental bi-directional interaction between telaprevir and ritonavir-boosted atazanavir, according to Spanish research published in the online edition of Clinical Infectious Diseases. The research involved 14 people with HIV and hepatitis C virus (HCV) co-infection who were ...

    25 November 2013 | Michael Carter
  • Studies look at community vs hospital-based HIV care and medication issues

    HIV-positive people treated at community clinics were more likely to continue receiving care, while those treated at hospital clinics were more likely to maintain undetectable viral load, researchers reported at IDWeek 2013 this week in San Francisco. Other studies ...

    07 October 2013 | Liz Highleyman
  • New NNRTI MK-1439 interacts with ritonavir but not tenofovir

    Blood levels of MK-1439, a next-generation HIV non-nucleoside reverse transcriptase inhibitor (NNRTI) in phase 2b trials, rose significantly when combined with ritonavir, but tenofovir had little effect, researchers reported at the 53rd Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC) ...

    17 September 2013 | Liz Highleyman
  • New tenofovir formulation works equally well with less effect on kidneys and bones

    Tenofovir alafenamide (TAF), a new formulation that produces higher drug levels in cells but allows for lower dosing, was as effective as the current tenofovir disoproxil fumarate (TDF) formulation, but had less impact on markers of kidney function and ...

    13 September 2013 | Liz Highleyman
  • Raltegravir is a good choice for people with HIV undergoing cancer chemotherapy

    The integrase inhibitor raltegravir (Isentress) may be an optimal choice for many HIV-positive people receiving cancer chemotherapy, as it is highly effective and well-tolerated in this population, according to a poster presentation at the 53rd Interscience Conference on Antimicrobial Agents and ...

    13 September 2013 | Liz Highleyman
  • High prevalence of heart rhythm disturbance among HIV-positive people on methadone maintenance therapy

    Spanish investigators have identified a high prevalence of a potentially life-threatening disturbance in heart rhythm among HIV-positive people receiving methadone maintenance therapy. ECG examinations showed that 36% of their participants had QTc prolongation, a condition that can lead to sudden cardiac-related ...

    13 August 2013 | Michael Carter
More news

Drug interactions and pharmacokinetics news selected from other sources

  • Isentress (raltegravir) label update

    On February 18, 2015, FDA approved changes to the Isentress (raltegravir) label to include updated information regarding the coadministration of raltegravir and aluminum and/or magnesium containing antacid.

    19 February 2015 | FDA
  • Viral Load Reductions Persist With Less Efavirenz for HIV

    The virologic responses with reduced-dose efavirenz at 48 weeks have proven durable out to 96 weeks, ENCORE1 study results show.

    07 November 2014 | Medscape (requires free registration)
  • Change to recommended regimen for post-exposure prophylaxis (PEP)

    The Expert Advisory Group on AIDS (EAGA) has recommended a change in the recommended regimen for post-exposure prophylaxis from tenofovir/emtricitabine with Kaletra to tenofovir/emtricitabine with raltegravir.

    11 September 2014 | Expert Advisory Group on AIDS (EAGA)
  • Dosage of HIV drug may be ineffective for half of African-Americans

    Many African-Americans may not be getting effective doses of the HIV drug maraviroc. The initial dosing studies included mostly European-Americans, who generally lack a protein that is key to removing maraviroc from the body, resulting in higher concentrations of the drug in the blood. The current study shows that people with maximum levels of the protein CYP3A5 -- including nearly half of African-Americans -- end up with lower levels of maraviroc in their bodies.

    28 August 2014 | Eurekalert Medicine & Health
  • Opioid Therapy No Bar to Novel HCV Drugs

    People on opioid substitution therapy for drug addiction can be safely and effectively treated for hepatitis C (HCV) with an investigational combination of medications, researchers said here.

    24 July 2014 | MedPage Today
  • Advice on Best ART Regimen for Patients Taking Cancer Therapy

    Because no clinical trials address the question and published data are insufficient to support guidelines, the optimal antiretroviral therapy (ART) regimen for patients undergoing cancer chemotherapy remains unknown. But experts from Houston’s M.D. Anderson Cancer Center offer suggestions to help clinicians individualize therapy for each patient.

    25 June 2014 | International AIDS Society
  • In HIV/TB coinfection, raltegravir may be an alternative to efavirenz

    Patients coinfected with HIV and tuberculosis (TB) may benefit from raltegravir as an alternative to efavirenz, new research suggests.

    02 June 2014 | Medscape
  • No critical interactions between ledipasvirsofosbuvir and certain key antiretrovirals

    Ledipasvir/sofosbuvir, a fixed-dose coformulation of two direct-acting antivirals (DAAs) for HCV infection, did not have a clinically significant impact on five frequently used antiretrovirals--raltegravir, efavirenz, rilpivirine, and tenofovir/emtricitabine (TDF/FTC)--according to results of three studies in healthy volunteers.

    29 May 2014 | NATAP
  • Calcium and Iron Supplements Lower Dolutegravir Levels When Taken Between Meals

    Calcium supplements taken with dolutegravir between meals lowered dolutegravir exposure by one third. Iron supplements with dolutegravir between meals approximately halved dolutegravir exposure. Supplements did not have this effect when taken with dolutegravir with a meal, or when dolutegravir was taken 2 hours before the supplement.

    24 May 2014 | NATAP
  • Better Late Than Never: Efavirenz Dose Optimization

    After a study suggests that we’ve been using too high a dose of efavirenz for a decade and a half, the move toward scaling up a lower and more cost-effective one faces some hurdles.

    03 April 2014 | Treatment Action Group
More news

Our information levels explained

  • Short and simple introductions to key HIV topics, sometimes illustrated with pictures.
  • Expands on the previous level, but also written in easy-to-understand plain language.
  • More detailed information, likely to include medical and scientific language.
  • Detailed, comprehensive information, using medical and specialised language.